VIX
40
2
BK
74
3
CTAS
28
-3
AMGN
36
-3
DAL
74
-2
CRM
57
7
BBY
41
-9
ADP
61
-3
CL
56
-2
ADM
48
-3
DUK
55
-2
AES
57
13
AAP
36
-5
EL
52
-10
ALL
57
-7
DVA
47
-3
AIG
56
3
ACN
56
-3
CAG
34
-3
AIZ
52
2
VIX
40
2
BK
74
3
CTAS
28
-3
AMGN
36
-3
DAL
74
-2
CRM
57
7
BBY
41
-9
ADP
61
-3
CL
56
-2
ADM
48
-3
DUK
55
-2
AES
57
13
AAP
36
-5
EL
52
-10
ALL
57
-7
DVA
47
-3
AIG
56
3
ACN
56
-3
CAG
34
-3
AIZ
52
2
Financhill
Back

Akero Therapeutics, Inc. 10K Form

Buy
66

AKRO
Akero Therapeutics, Inc.

Last Price:
$54.62
Seasonality Move:
21.2%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive AKRO News And Ratings

See the #1 stock for the next 7 days that we like better than AKRO

AKRO Financial Statistics

Sales & Book Value

Annual Sales: $0
Cash Flow: $-67.2M
Price / Cash Flow: 0
Annual Sales: $11.95
Price / Book: 4.7

Profitability

EPS (TTM): -3.74880
Net Income (TTM): $-292.8M
Gross Margin: $-18K
Return on Equity: -32.14%
Return on Assets: -29.79%

Akero Therapeutics, Inc. Earnings Forecast

Key Akero Therapeutics, Inc. Financial Ratios

  • Per Share Earnings over the last 7 years have been positive in 3 years.

Akero Therapeutics, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: AKRO
CUSIP: 00973Y
Website: akerotx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 15.83
Quick Ratio: 15.48

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

AKRO Technical Analysis vs Fundamental Analysis

Buy
66
Akero Therapeutics, Inc. (AKRO) is a Buy

Is Akero Therapeutics, Inc. a Buy or a Sell?